Roche starts another Tarceva trial

OSI Pharmaceuticals (OSIP) said partner Roche (SWX:ROCZ) started a 1,000-patient Phase III trial of OSIP'sTarceva ( OSI-774) EGFR antagonist in combination with gemcitabine for non-small cell lung can...